Results 201 to 210 of about 99,632 (265)

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Multi-omics profiling of pancreatic neuroendocrine tumors: Interplay of genomic instability and the tumor microenvironment (Review). [PDF]

Oncol Lett
Wan Y, Zhang Y, Philip PA, Chen H, El-Rayes B, Azmi AS, Shi Y.   +6 more
europepmc   +1 more source

A Collateral Venous Pathway in Omental Arch of Barkow After Spleen Preserving Distal Pancreatectomy

ANZ Journal of Surgery, EarlyView.
Carmine Cartanese, Matteo Scaramuzzi, Raffaele De Luca, Giovanni Mastrandrea, Mario Sollitto   +4 more
wiley   +1 more source

Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐TAIL‐2

Cancer Science, EarlyView.
BLURB FOR ETOC: The J‐TAIL‐2 study (NCT04501497) evaluated the efficacy and safety of atezolizumab, an anti‐programmed death‐ligand 1, plus chemotherapy in patients with non‐small cell lung cancer (NSCLC) and extensive‐stage small cell lung cancer (ES‐SCLC) in real‐world settings.
Yasushi Goto, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Junichi Shimizu, Eisaku Miyauchi, Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Yasutaka Watanabe, Nobuyuki Katakami, Akira Kisohara, Masafumi Yamaguchi, Hirotaka Kuroki, Masamichi Sugimoto, Hisao Ashimura, Misa Tanaka, Akihiko Gemma   +19 more
wiley   +1 more source

Somatostatin analogs in neuroendocrine tumors with Ki-67 index of ≥10. [PDF]

J Neuroendocrinol
Braegelmann J, Mathew A, Schmidt B, Kalisch H, Fendler WP, Führer-Sakel D, Lahner H.   +6 more
europepmc   +1 more source

Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes

Cancer Science, EarlyView.
Afatinib and osimertinib showed broadly comparable survival outcomes as first‐line therapy for NSCLC with uncommon EGFR mutations. Treatment may be individualized by mutation subtype, while adding immune checkpoint inhibition to platinum doublet after EGFR‐TKI showed no clear benefit.
Yutaro Nagano, Hiroshi Yokouchi, Ryota Saito, Osamu Honjo, Toshiyuki Sumi, Takayuki Kaburagi, Kenichiro Ito, Yasuyuki Ikezawa, Keiki Yokoo, Hajime Kikuchi, Sayaka Kudo, Masami Yamazoe, Ryota Shigaki, Keita Tagami, Toshiyuki Tenma, Tatsuru Ishikawa, Mamoru Takahashi, Takaaki Sasaki, Hajime Asahina, Shiro Hinotsu, Hirofumi Chiba, Satoshi Oizumi   +21 more
wiley   +1 more source

Patient-reported symptom and urgent healthcare use in neuroendocrine tumors. [PDF]

Endocr Oncol
Hallet J, Noel C, Sutradhar R, Duncan K, Law C, Singh S, Myrehaug S, Coburn N, Chan WC, Gombay A, Eskander A.   +10 more
europepmc   +1 more source

Radiomic Analysis for Ki-67 Classification in Small Bowel Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Checchin F, Malerba D, Gambella A, Puleri AR, Sambuceti V, Vanoli A, Grillo F, Preda L, Bortolotto C.   +8 more
europepmc   +1 more source

Comparing Response Evaluation Methods for PRRT in Neuroendocrine Tumors: Insights from an Exploratory Study. [PDF]

Cancers (Basel)
Guglielmo P, Carnaghi C, Bertuzzi AF, Laffi A, Damiani S, Riva UC, Olivieri M, Marenco M, Evangelista L.   +8 more
europepmc   +1 more source

The impact of radioligand therapy on prognosis in patients with lung neuroendocrine tumors. [PDF]

Front Endocrinol (Lausanne)
Jóźwik-Plebanek K, Saracyn M, Durma AD, Kołodziej M, Mądra W, Dziuk M, Janiak K, Balcerska Z, Gniadek-Olejniczak K, Kamiński G.   +9 more
europepmc   +1 more source